Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Commun Biol. 2021 Mar 23;4(1):392. doi: 10.1038/s42003-021-01910-y.
Idiopathic pulmonary fibrosis (IPF) is a fatal disorder characterised by progressive, destructive lung scarring. Despite substantial progress, the genetic determinants of this disease remain incompletely defined. Using whole genome and whole exome sequencing data from 752 individuals with sporadic IPF and 119,055 UK Biobank controls, we performed a variant-level exome-wide association study (ExWAS) and gene-level collapsing analyses. Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G > A p.Arg20Gln; p = 2.4 × 10, odds ratio = 2.87, 95% confidence interval: 2.03-4.07). This signal was independently replicated in the FinnGen cohort, which contains 1028 cases and 196,986 controls (combined p = 2.2 × 10), firmly associating this variant as an IPF risk allele. SPDL1 encodes Spindly, a protein involved in mitotic checkpoint signalling during cell division that has not been previously described in fibrosis. To the best of our knowledge, these results highlight a novel mechanism underlying IPF, providing the potential for new therapeutic discoveries in a disease of great unmet need.
特发性肺纤维化 (IPF) 是一种致命疾病,其特征为进行性、破坏性肺瘢痕形成。尽管取得了重大进展,但该疾病的遗传决定因素仍未完全确定。我们使用来自 752 名散发性 IPF 患者和 119,055 名英国生物库对照者的全基因组和全外显子组测序数据,进行了变异水平外显子组全关联研究 (ExWAS) 和基因水平合并分析。我们的变异水平分析揭示了 SPDL1 中的一个罕见错义变异与 IPF 之间的新关联 (NM_017785.5:g.169588475 G > A p.Arg20Gln;p = 2.4 × 10,优势比 = 2.87,95%置信区间:2.03-4.07)。该信号在包含 1028 例病例和 196,986 例对照者的 FinnGen 队列中得到了独立复制(合并 p = 2.2 × 10),明确将该变异体确认为 IPF 风险等位基因。SPDL1 编码 Spindly,这是一种在细胞分裂过程中参与有丝分裂检查点信号传导的蛋白质,以前在纤维化中尚未描述过。据我们所知,这些结果突出了 IPF 的一个新机制,为这种具有巨大未满足需求的疾病提供了新的治疗发现潜力。